

**Evaluation of affibody charge modification identified by synthetic consensus design in molecular PET imaging of epidermal growth factor receptor**

Brett A. Case, Max A. Kruziki, Lawrence A. Stern, and Benjamin J. Hackel

Department of Chemical Engineering and Materials Science


University of Minnesota – Twin Cities

Minneapolis, MN


*Supplementary Figures and Tables*

| Variant | Yield (mg/L) | K <sub>d</sub> (nM) | T <sub>m</sub> (°C) | 2° Structure | Specificity<br>(A431:MCF7 Binding Signals) |
|---------|--------------|---------------------|---------------------|--------------|--|
| EA68    | 3.5 ± 0.3    | 5.3 ± 1.7           | 71                  | α-helical    | 109 ± 63                                   |
| EA26S   | 0.62 ± 0.02  | 1.6 ± 1.2           | 68                  | α-helical    | 214 ± 134                                  |
| EA62S   | 1.9 ± 0.3    | 2.5 ± 0.7           | 59                  | α-helical    | 342 ± 209                                  |
| EA35S   | 7.0 ± 0.5    | 1.7 ± 0.5           | 68                  | α-helical    | 529 ± 297                                  |
| EA35C   | 12.7 ± 0.9   | 6.9 ± 1.4           | 71                  | α-helical    | 74 ± 29                                    |



**Supplemental Table 1.** Biophysical properties of affibody clones used for PET/CT imaging.




**Supplemental Figure 1.** Matrix-assisted laser desorption ionization mass spectrometry (MALDI-MS) of NODAGA-Affibody charge variants with 0, 1, 2, or 3 degrees of conjugation



**Supplemental Figure 2.** *NODAGA-Affibody target-affinity characterization.* EGFR-overexpressing A431 cells were mixed with the indicated concentration of NODAGA-conjugated affibody. Binding was detected with fluorophore-conjugated anti-His6 antibody via flow cytometry. Equilibrium dissociation constants were calculated assuming a 1:1 binding model.  $n = 3$  measurements per variant. NODAGA-conjugated versions of EA35S and EA26 were nominally weaker binders to EGFR than their unconjugated counterparts ( $K_d = 3.9 \pm 0.4$  nM vs.  $1.7 \pm 0.5$  nM and  $4.6 \pm 0.3$  vs.  $1.6 \pm 1.2$  nM respectively). However, these variances are slight and should not meaningfully impact *in vivo* biomarker localization. EA68 and EA62 showed no difference in binding affinity upon NODAGA conjugation and EA35C presented a slight improvement ( $4.3 \pm 0.3$  nM vs.  $6.9 \pm 1.4$  nM).



**Supplemental Figure 3.** Matrix-assisted laser desorption ionization mass spectrometry (MALDI-MS) of DOTA-Affibody charge variants with 0, 1, 2, or 3 degrees of conjugation



**Supplemental Figure 4.** Radio chromatography of affibody clones left untreated, in serum, or in trypsin.